With 1 ETF traded in the U.S. markets, MVIS US Listed Biotech 25 Index ETF gathers total assets under management of $566.50M. The average expense ratio is 0.35%. MVIS US Listed Biotech 25 Index ETF can be found in the following asset class:
- Equity
With 1 ETF traded in the U.S. markets, MVIS US Listed Biotech 25 Index ETF gathers total assets under management of $566.50M. The average expense ratio is 0.35%. MVIS US Listed Biotech 25 Index ETF can be found in the following asset class:
It's easy to be blinded by headline numbers. The rally in biotech isn't so simple.
ETFs are becoming core holdings for institutions.
High-flying ETFs in several sectors eclipsed the S&P 500 gains.
Multiple factors are setting the sector up for further growth in 2014.
The latest tally of year-to-date top-10-performing ETFs include Japan, clean energy and biotech funds, to name a few.
Who knew Egypt would be the best ETF as the third quarter draws to a close?